Developer docs
API playgroundTry for free, no card

Search company profiles

Envol Biomedical

Full company profile

uuid000et59

Namestring
Envol Biomedical
Legal namestring
Envol Biomedical
Websiteurl
envolbio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Envol Biomedical is a private, US-based preclinical contract research organization founded in 2019, headquartered in New City. The company specializes in non-human primate (NHP) research services for pharmaceutical and biotech sponsors developing small molecules, biologics, and gene therapies, and positions itself as the largest provider of NHP subjects in North America. Operations run from a 75,000+ square foot AAALAC-accredited, USDA-registered, and OLAW-compliant facility with GLP compliance, vertically integrating breeding and colony management with downstream study execution.

The company's product platform spans pharmacology services, pharmacokinetics (PK), GLP and non-GLP toxicology, core laboratory and bioanalytical services, imaging, and surgical capabilities including MRI-guided neurosurgery delivered through a partnership with ClearPoint Neuro. Specialized therapeutic area coverage includes obesity and metabolic disease, gene therapy, CNS, respiratory, and ocular indications. An AI-enabled toxicology reporting platform was launched in 2024 for real-time data transformation, and the company participates in the LNP Alliance with NeoSome Life Sciences, NIS Nanoimaging Services, and Phosphorex for lipid nanoparticle and gene therapy research. Other operational partners include ODIN Bioscience (biological matrices), TOXPLUS (GLP monitoring), Resero (PK modeling), and Endpoint Preclinical.

Envol operates a professional services, quote-based revenue model with multi-year enterprise contracts. Go-to-market relies on direct enterprise field sales targeting pharma and biotech decision-makers and study directors, supplemented by active presence at major industry conferences (SOT, BIO, ACT, ASGCT), scientific publications and thought leadership, and webinars with partners. The leadership team includes veterans of Lovelace Biomedical, Charles River Laboratories, Biomere, SNBL USA, and academic institutions including Johns Hopkins, Stanford, and NIH. The company is founder/management-led with no disclosed institutional investment or funding rounds.

Short descriptiontext

Envol Biomedical is a private US preclinical contract research organization providing non-human primate-based pharmacology, pharmacokinetics, toxicology, imaging, surgical, and bioanalytical services to pharmaceutical and biotech sponsors, operating the largest NHP supply in North America from a 75,000+ sq ft facility.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew City, United States
HQ citystring
New City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
preclinical contract research, nonhuman primate models, GLP toxicology services, pharmacokinetics ADME studies, preclinical drug development
Industry1 code
PRIMARYHLACAOAA
Electronic Data Capture (EDC) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Preclinical Contract Research Services
TypeProfessional Services
Description

Contract research services encompassing pharmacology, pharmacokinetics, toxicology, imaging, and surgical services for pharmaceutical and biotech companies developing therapeutics.

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Custom contract research pricing based on study scope and requirements
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing tailored to individual study requirements, including scope of work, species requirements, study duration, and specialized capabilities needed.

GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Envol Biomedical is a preclinical contract research organization that provides non-human primate (NHP)-based pharmacology, pharmacokinetics, toxicology, surgical, imaging, core laboratory, and biological matrices services for pharmaceutical and biotech sponsors. The company also operates an AAALAC-accredited NHP breeding and colony management program, making it the largest provider of NHP subjects in North America, and delivers integrated GLP-compliant study execution from discovery through IND-enabling development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Largest NHP subject provider in North America
Product overview1 text field

Envol Biomedical operates as a preclinical contract research organization (CRO) offering an integrated platform of services for drug development. The core offering includes Pharmacology Services, Pharmacokinetics (PK) Services with Resero integration, Toxicology Services with AI-enabled reporting and TOXPLUS GLP monitoring, Core Laboratory Services with biological matrix capabilities, and Imaging Services including MRI-guided neurosurgical capabilities via ClearPoint Neuro. The company provides Breeding & Colony Management services and extends its offerings through the LNP Alliance Partnership program with NeoSome Life Sciences, NIS Nanoimaging Services, and Phosphorex. All services maintain GLP compliance with SEND compatibility for regulatory submissions.

Product and service8 records
1Pharmacology Services
CategoryPreclinical Contract Research Services
Description

Translational pharmacology studies in non-human primate (NHP) models, including efficacy testing, dose-response, and mechanism of action investigations for drug development programs. Designed for pharmaceutical and biotech sponsors advancing small molecules, biologics, and gene therapies.

2Pharmacokinetics (PK) Services
CategoryPreclinical Contract Research Services
Description

Advanced pharmacokinetic studies in NHPs delivering ADME (absorption, distribution, metabolism, and excretion) profiling, with PK modeling and reporting supported by Resero integration. Targeted at pharmaceutical and biotech sponsors needing IND-enabling PK data.

3Toxicology Services
CategoryPreclinical Contract Research Services
Description

GLP-compliant toxicology programs in NHPs, including acute, subchronic, and chronic toxicity assessments, with AI-enabled reporting and TOXPLUS-powered monitoring. Built to accelerate IND readiness for pharmaceutical and biotech sponsors.

4Core Laboratory Services
CategoryPreclinical Contract Research Services
Description

Comprehensive analytical, bioanalytical, and molecular assay support including sample analysis, biomarker quantification, and biological matrix analysis through ODIN Bioscience integration. Provides the data backbone for pharmacology, PK, and toxicology studies.

5Imaging Services
CategoryPreclinical Contract Research Services
Description

Advanced imaging capabilities integrated across preclinical programs, including MRI-guided neurosurgical procedures through the ClearPoint Neuro partnership. Supports surgical precision, disease modeling, and data interpretation in NHP studies.

6Surgical Capabilities
CategoryPreclinical Contract Research Services
Description

In-house surgical team enabling complex dosing, serial sampling, and targeted delivery in NHP studies with clinical-grade precision and cross-functional coordination. Includes MRI-guided neurosurgery via ClearPoint Neuro.

7Breeding & Colony Management
CategoryPreclinical Contract Research Services
Description

AAALAC-accredited, USDA-registered, OLAW-compliant in-house breeding and colony management programs ensuring animal health, genetic integrity, and regulatory compliance. Provides consistent, study-ready NHP models for pharmacology, toxicology, and surgical research.

8Biological Matrices
CategoryPreclinical Contract Research Services
Description

High-quality biological matrices including blood, tissues, cells, and biofluids sourced through ODIN Bioscience and integrated into GLP laboratory workflows for reliable, reproducible research outcomes.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1ODIN Bioscience
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership providing biological matrices for preclinical research studies, supporting Envol's comprehensive service offerings in toxicology and pharmacokinetics.

2LNP Alliance
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Envol serves as the expert NHP partner within the LNP Alliance, collaborating with NeoSome Life Sciences, NIS Nanoimaging Services, and Phosphorex to provide integrated solutions for lipid nanoparticle and gene therapy research.

3TOXPLUS
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for GLP study monitoring services, combining Envol's NHP research capabilities with TOXPLUS's toxicology expertise for comprehensive preclinical safety assessment.

Strategic tierSupportingTypeTechnology or Integration
Description

Partnership for pharmacokinetic modeling and reporting services, integrating Envol's study execution with Resero's analytical and modeling capabilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration providing MRI-guided neurosurgical capabilities for complex CNS and gene therapy preclinical studies, enabling precise delivery and assessment of therapeutic candidates.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Partnership to expand capabilities and provide comprehensive preclinical solutions, leveraging complementary expertise and infrastructure.

Strategic tierSupportingTypeGTM or Marketing Partner
Description

Joint marketing and presentation partnership at ACT 2025 conference, showcasing combined regulatory toxicology expertise to prospective clients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Member of LNP Alliance, collaborating on lipid nanoparticle research with Envol providing NHP expertise.

9NIS Nanoimaging Services
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Member of LNP Alliance, providing nanoimaging capabilities for nanoparticle and gene therapy biodistribution studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Member of LNP Alliance, contributing formulation and delivery expertise for nanoparticle-based therapeutics research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Preclinical CRO where Envol's CEO Jake McDonald was previously CSO/VP. Competes in the same NHP toxicology and inhalation pharmacology space with similar therapeutic area coverage.

TypeBroad incumbent
Description

Global CRO with large preclinical and biologics capacity. Competes for outsourced pharma R&D programs, though geopolitical scrutiny of WuXi has redirected some U.S. sponsor work toward domestic NHP providers like Envol.

TypeBroad incumbent
Description

Global CRO offering integrated preclinical and clinical services. Competes with Envol for multi-modality pharma outsourcing programs where sponsors prefer bundled providers.

TypeEmerging player
Description

Mid-sized preclinical CRO providing GLP toxicology, pharmacology, and analytical services to pharma and biotech. Comparable in scale to Envol with overlapping capabilities in regulatory-grade preclinical studies.

TypeDirect peer
Description

NHP-specialized preclinical CRO with primate breeding and toxicology capabilities. Envol's attending veterinarian formerly directed SNBL USA's primate facility, making SNBL one of the closest direct comparables in NHP-focused preclinical services.

TypeBroad incumbent
Description

Largest clinical CRO with preclinical capabilities. Represents an entrenched competitor for large pharma outsourcing relationships, particularly where clients value end-to-end preclinical-to-Phase IV coverage.

TypeDirect peer
Description

NHP-focused preclinical CRO offering toxicology, pharmacology, and surgical services. Envol's co-founder Alain Stricker-Krongrad previously held a C-suite role at Sinclair, and the two compete for the same NHP IND-enabling study budget.

8MPI Research (now part of Charles River)
TypeBroad incumbent
Description

Preclinical CRO specializing in safety assessment, including NHP studies. Now integrated into Charles River, it competes with Envol for IND-enabling toxicology work; Envol's Technical Operations Manager previously worked at MPI.

TypeBroad incumbent
Description

Largest NHP and broader preclinical CRO globally. Envol's co-founder previously held a C-suite role here, and Charles River remains the dominant incumbent Envol directly competes against for large pharma preclinical programs.

TypeDirect peer
Description

Preclinical CRO specializing in NHP and rodent toxicology/pharmacology. Another former employer of Envol's co-founder, Biomere is a direct competitor for NHP safety assessment and efficacy studies.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Envol Biomedical

Preclinical Contract Research Servicesenvolbio.com

Envol Biomedical is a private US preclinical contract research organization providing non-human primate-based pharmacology, pharmacokinetics, toxicology, imaging, surgical, and bioanalytical services to pharmaceutical and biotech sponsors, operating the largest NHP supply in North America from a 75,000+ sq ft facility.

What Envol Biomedical does

Envol Biomedical is a private, US-based preclinical contract research organization founded in 2019, headquartered in New City. The company specializes in non-human primate (NHP) research services for pharmaceutical and biotech sponsors developing small molecules, biologics, and gene therapies, and positions itself as the largest provider of NHP subjects in North America. Operations run from a 75,000+ square foot AAALAC-accredited, USDA-registered, and OLAW-compliant facility with GLP compliance, vertically integrating breeding and colony management with downstream study execution.

The company's product platform spans pharmacology services, pharmacokinetics (PK), GLP and non-GLP toxicology, core laboratory and bioanalytical services, imaging, and surgical capabilities including MRI-guided neurosurgery delivered through a partnership with ClearPoint Neuro. Specialized therapeutic area coverage includes obesity and metabolic disease, gene therapy, CNS, respiratory, and ocular indications. An AI-enabled toxicology reporting platform was launched in 2024 for real-time data transformation, and the company participates in the LNP Alliance with NeoSome Life Sciences, NIS Nanoimaging Services, and Phosphorex for lipid nanoparticle and gene therapy research. Other operational partners include ODIN Bioscience (biological matrices), TOXPLUS (GLP monitoring), Resero (PK modeling), and Endpoint Preclinical.

Envol operates a professional services, quote-based revenue model with multi-year enterprise contracts. Go-to-market relies on direct enterprise field sales targeting pharma and biotech decision-makers and study directors, supplemented by active presence at major industry conferences (SOT, BIO, ACT, ASGCT), scientific publications and thought leadership, and webinars with partners. The leadership team includes veterans of Lovelace Biomedical, Charles River Laboratories, Biomere, SNBL USA, and academic institutions including Johns Hopkins, Stanford, and NIH. The company is founder/management-led with no disclosed institutional investment or funding rounds.

Envol Biomedical firmographics

Firmographics
Name
Envol Biomedical
Legal name
Envol Biomedical
Website
https://envolbio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Envol Biomedical is a private US preclinical contract research organization providing non-human primate-based pharmacology, pharmacokinetics, toxicology, imaging, surgical, and bioanalytical services to pharmaceutical and biotech sponsors, operating the largest NHP supply in North America from a 75,000+ sq ft facility.
Ownership category
akta.pro rank

Envol Biomedical industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACAOAA
Electronic Data Capture (EDC) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Preclinical contract research
  • Nonhuman primate models
  • GLP toxicology services
  • Pharmacokinetics ADME studies
  • Preclinical drug development

Where Envol Biomedical is headquartered

Location

Headquarters

HQ city
New City
HQ country
United States
HQ region
North America

Markets served

Envol Biomedical business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Preclinical Contract Research Services: Contract research services encompassing pharmacology, pharmacokinetics, toxicology, imaging, and surgical services for pharmaceutical and biotech companies developing therapeutics.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom contract research pricing based on study scope and requirements

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Envol Biomedical product offering

Product offering

Core offering

Envol Biomedical is a preclinical contract research organization that provides non-human primate (NHP)-based pharmacology, pharmacokinetics, toxicology, surgical, imaging, core laboratory, and biological matrices services for pharmaceutical and biotech sponsors. The company also operates an AAALAC-accredited NHP breeding and colony management program, making it the largest provider of NHP subjects in North America, and delivers integrated GLP-compliant study execution from discovery through IND-enabling development.

Product overview

Envol Biomedical operates as a preclinical contract research organization (CRO) offering an integrated platform of services for drug development. The core offering includes Pharmacology Services, Pharmacokinetics (PK) Services with Resero integration, Toxicology Services with AI-enabled reporting and TOXPLUS GLP monitoring, Core Laboratory Services with biological matrix capabilities, and Imaging Services including MRI-guided neurosurgical capabilities via ClearPoint Neuro. The company provides Breeding & Colony Management services and extends its offerings through the LNP Alliance Partnership program with NeoSome Life Sciences, NIS Nanoimaging Services, and Phosphorex. All services maintain GLP compliance with SEND compatibility for regulatory submissions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmacology Services Translational pharmacology studies in non-human primate (NHP) models, including efficacy testing, dose-response, and mechanism of action investigations for drug development programs. Designed for pharmaceutical and biotech sponsors advancing small molecules, biologics, and gene therapies.
  • Pharmacokinetics (PK) Services Advanced pharmacokinetic studies in NHPs delivering ADME (absorption, distribution, metabolism, and excretion) profiling, with PK modeling and reporting supported by Resero integration. Targeted at pharmaceutical and biotech sponsors needing IND-enabling PK data.
  • Toxicology Services GLP-compliant toxicology programs in NHPs, including acute, subchronic, and chronic toxicity assessments, with AI-enabled reporting and TOXPLUS-powered monitoring. Built to accelerate IND readiness for pharmaceutical and biotech sponsors.
  • Core Laboratory Services Comprehensive analytical, bioanalytical, and molecular assay support including sample analysis, biomarker quantification, and biological matrix analysis through ODIN Bioscience integration. Provides the data backbone for pharmacology, PK, and toxicology studies.
  • Imaging Services Advanced imaging capabilities integrated across preclinical programs, including MRI-guided neurosurgical procedures through the ClearPoint Neuro partnership. Supports surgical precision, disease modeling, and data interpretation in NHP studies.
  • Surgical Capabilities In-house surgical team enabling complex dosing, serial sampling, and targeted delivery in NHP studies with clinical-grade precision and cross-functional coordination. Includes MRI-guided neurosurgery via ClearPoint Neuro.
  • Breeding & Colony Management AAALAC-accredited, USDA-registered, OLAW-compliant in-house breeding and colony management programs ensuring animal health, genetic integrity, and regulatory compliance. Provides consistent, study-ready NHP models for pharmacology, toxicology, and surgical research.
  • Biological Matrices High-quality biological matrices including blood, tissues, cells, and biofluids sourced through ODIN Bioscience and integrated into GLP laboratory workflows for reliable, reproducible research outcomes.

Quantifiable outcome

  • Largest NHP subject provider in North America

Companies that use Envol Biomedical

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Envol Biomedical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability4 records

Feature3 records

Envol Biomedical partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and supporting.

  • ODIN BiosciencecoreStrategic or Co-development PartnerStrategic partnership providing biological matrices for preclinical research studies, supporting Envol's comprehensive service offerings in toxicology and pharmacokinetics.
  • LNP AlliancecoreStrategic or Co-development PartnerEnvol serves as the expert NHP partner within the LNP Alliance, collaborating with NeoSome Life Sciences, NIS Nanoimaging Services, and Phosphorex to provide integrated solutions for lipid nanoparticle and gene therapy research.
  • TOXPLUScoreStrategic or Co-development PartnerCollaboration for GLP study monitoring services, combining Envol's NHP research capabilities with TOXPLUS's toxicology expertise for comprehensive preclinical safety assessment.
  • ReserosupportingTechnology or IntegrationPartnership for pharmacokinetic modeling and reporting services, integrating Envol's study execution with Resero's analytical and modeling capabilities.
  • ClearPoint NeurocoreStrategic or Co-development PartnerCollaboration providing MRI-guided neurosurgical capabilities for complex CNS and gene therapy preclinical studies, enabling precise delivery and assessment of therapeutic candidates.
  • Endpoint PreclinicalsupportingStrategic or Co-development PartnerPartnership to expand capabilities and provide comprehensive preclinical solutions, leveraging complementary expertise and infrastructure.
  • White Oak Regulatory ToxsupportingGTM or Marketing PartnerJoint marketing and presentation partnership at ACT 2025 conference, showcasing combined regulatory toxicology expertise to prospective clients.
  • NeoSome Life SciencescoreStrategic or Co-development PartnerMember of LNP Alliance, collaborating on lipid nanoparticle research with Envol providing NHP expertise.
  • NIS Nanoimaging ServicescoreStrategic or Co-development PartnerMember of LNP Alliance, providing nanoimaging capabilities for nanoparticle and gene therapy biodistribution studies.
  • PhosphorexcoreStrategic or Co-development PartnerMember of LNP Alliance, contributing formulation and delivery expertise for nanoparticle-based therapeutics research.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Envol Biomedical competitors and assessment

Company assessment

Direct peers

  • Lovelace Biomedical Research Institute: Preclinical CRO where Envol's CEO Jake McDonald was previously CSO/VP. Competes in the same NHP toxicology and inhalation pharmacology space with similar therapeutic area coverage.
  • SNBL USA: NHP-specialized preclinical CRO with primate breeding and toxicology capabilities. Envol's attending veterinarian formerly directed SNBL USA's primate facility, making SNBL one of the closest direct comparables in NHP-focused preclinical services.
  • Sinclair Research: NHP-focused preclinical CRO offering toxicology, pharmacology, and surgical services. Envol's co-founder Alain Stricker-Krongrad previously held a C-suite role at Sinclair, and the two compete for the same NHP IND-enabling study budget.
  • Biomere: Preclinical CRO specializing in NHP and rodent toxicology/pharmacology. Another former employer of Envol's co-founder, Biomere is a direct competitor for NHP safety assessment and efficacy studies.

Broad incumbents

  • WuXi AppTec: Global CRO with large preclinical and biologics capacity. Competes for outsourced pharma R&D programs, though geopolitical scrutiny of WuXi has redirected some U.S. sponsor work toward domestic NHP providers like Envol.
  • Labcorp Drug Development (Covance): Global CRO offering integrated preclinical and clinical services. Competes with Envol for multi-modality pharma outsourcing programs where sponsors prefer bundled providers.
  • IQVIA: Largest clinical CRO with preclinical capabilities. Represents an entrenched competitor for large pharma outsourcing relationships, particularly where clients value end-to-end preclinical-to-Phase IV coverage.
  • MPI Research (now part of Charles River): Preclinical CRO specializing in safety assessment, including NHP studies. Now integrated into Charles River, it competes with Envol for IND-enabling toxicology work; Envol's Technical Operations Manager previously worked at MPI.
  • Charles River Laboratories: Largest NHP and broader preclinical CRO globally. Envol's co-founder previously held a C-suite role here, and Charles River remains the dominant incumbent Envol directly competes against for large pharma preclinical programs.

Emerging players

  • Pacific BioLabs: Mid-sized preclinical CRO providing GLP toxicology, pharmacology, and analytical services to pharma and biotech. Comparable in scale to Envol with overlapping capabilities in regulatory-grade preclinical studies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Envol Biomedical compliance and trust

Trust signal

Compliance4 records

Envol Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Envol Biomedical leadership team

Management profile

Number of profiles

Profiles11 records

Envol Biomedical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Envol Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Envol Biomedical

What does Envol Biomedical do?

Envol Biomedical is a preclinical contract research organization that provides non-human primate (NHP)-based pharmacology, pharmacokinetics, toxicology, surgical, imaging, core laboratory, and biological matrices services for pharmaceutical and biotech sponsors. The company also operates an AAALAC-accredited NHP breeding and colony management program, making it the largest provider of NHP subjects in North America, and delivers integrated GLP-compliant study execution from discovery through IND-enabling development.

Is Envol Biomedical a public or private company?

Envol Biomedical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Envol Biomedical founded?

Envol Biomedical was founded in 2019. It employs 11 to 50 people.

Where is Envol Biomedical based?

Envol Biomedical is headquartered in New City, United States, in the North America region.

How does Envol Biomedical make money?

One revenue line is on record: preclinical Contract Research Services.

Who are Envol Biomedical's main competitors?

Direct peers on record are Lovelace Biomedical Research Institute, SNBL USA, Sinclair Research and Biomere. Broad incumbents are WuXi AppTec, Labcorp Drug Development (Covance), IQVIA, MPI Research (now part of Charles River) and Charles River Laboratories. Pacific BioLabs is listed as an emerging player.

Does Envol Biomedical have an API?

No public API is recorded for Envol Biomedical.

What industry is Envol Biomedical in?

Envol Biomedical's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLACAOAA, Electronic Data Capture (EDC) Platforms. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals